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Abstract 
Lumbar sympathetic block is an analgesic procedure frequently performed in chronic pain clinics 
for ischemic lower limb pain from peripheral arterial disease. Although the lumbar sympathetic 
ganglia are anatomically near major vascular and neural structures, complications such as severe 
hemorrhage is rarely reported. Aspirin/extended release dipyridamole (Aggrenox) is indicated 
for secondary stroke prevention. Stroke is frequently a co-morbid condition in patients with pe-
ripheral vascular disease. Interventional pain physicians frequently face the difficulty of deciding 
whether to continue or stop antithrombotic medications in the periprocedural period because of 
the devastating consequences of both hemorrhagic and thrombotic complications. Due to a pauci-
ty of data, no guidelines have been specifically written for interventional procedures for chronic 
pain. To aid future decision making, we present a case report of psoas hematoma developed after 
lumbar sympathetic block in a patient with end stage renal failure and hepatic dysfunction who 
had limb-threatening ischemia. The patient was treated with Aggrenox until three days before the 
procedure. 
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1. Introduction 
Aspirin/extended release dipyridamole (Aggrenox) is a combination antiplatelet agent that is approved for sec-
ondary stroke prevention by the Food and Drug Administration [1]. The incidence of stroke rises progressively 
with age [2], so does the chronic pain from degenerative spine and vascular diseases. Facing a growing aging 
population, interventional pain physicians frequently confront the dilemma of whether to stop or continue anti-
platelet/ anticoagulation agents in the periprocedural period. Presently, no guidelines have been written specifi-
cally for the management of antiplatelet/anticoagulation therapy around the time of chronic pain-relieving pro-
cedures. Common practice has been followed American Society of Regional Anesthesia and Pain Medicine 
(ASRA) recommendations for the management of antithrombotic therapy when neuraxial and peripheral tech-
niques are performed [3]. To aid future decision making, we present here a case report of psoas hematoma de-
veloped after lumbar sympathetic block in a patient with end stage renal failure and liver disease who had 
limb-threatening ischemia. The patient was treated with Aggrenox until three days before the procedure. 
2. Case Report 
A 77 year-old white male was referred to the pain clinic for resting left foot pain with gangrene secondary to 
severe peripheral vascular disease. His past medical history included atherosclerotic coronary heart disease, 
congestive heart failure, aortic stenosis, atrial fibrillation, end stage renal disease on peritoneal dialysis, and dys-
lipidemia. Gangrene of the toes of his left foot was noted five months prior to the office visit and his left fourth 
toe was amputated three weeks prior. Relentless resting pain in the left foot and calf was uncontrolled by oral 
pain medications. Surgical revascularization or angioplasty was considered but deterred due to concerns of 
complications. A lumbar sympathetic block (LSB) was considered as a less invasive pain relieving procedure. 
The patient was taken Aggrenox for secondary stroke prevention. This was prescribed after he developed ga-
strointestinal bleeding while taking warfarin. Aggrenox was discontinued three days before the LSB. His other 
medications were Prilosec 20 mg daily, prednisone 20 mg daily, metoprolol 25 mg twice a day, Percocet 7.5/325 
every four hours as needed, MiraLAX 17 grams daily, and Nephrocaps daily. Physical examination revealed red, 
purplish skin discoloration of the left great and second toes. No palpable dorsal pedal pulses were found bilate-
rally, but femoral pulses were felt. The temperatures before the sympathetic block were left leg 83.7 F and right 
leg 83.9 F.  
After discussing the risks and benefits of LSB, the patient gave consent and was taken to the fluoroscopy suite. 
He was placed in the prone position with monitors attached to him. The procedure site, 8 cm lateral to the area 
corresponding to the anterolateral aspect of the upper 1/3 of the L3 vertebra, was prepped as for an aseptic pro-
cedure. After the skin and subcutaneous tissue was anesthetized with 1% lidocaine, under fluoroscopy guidance, 
a 7" bend spinal needle was placed at the anterolateral aspect of the upper 1/3 of the L3 vertebrae. The needle 
position was confirmed using Isovue dye. After negative aspiration for blood and cerebral spinal fluid, 5 ml of 
0.25% bupivacaine was injected. The procedure was completed with one attempt. The patient was transferred to 
the recovery area for observation. Approximately 15 minutes later, the patient became pale and developed se-
vere back pain, abdominal pain, and nausea with vomiting. The patient’s blood pressure dropped to 70/40 
mmHg associated with mottled skin on the left flank. Intravenous fluid was initiated and the patient was admit-
ted to the intensive care unit of the hospital. 
The patient’s admission lab data are shown in Table 1. His electrocardiogram revealed nonspecific ST-T 
wave changes. Abdominal CT scan showed an enlarged left psoas muscle with fluid around it and extending an-
teriorly into the abdomen (Figure 1). Additional CT images of the patient’s liver revealed inhomogeneous den-
sity that was suggestive of cirrhosis with abdominal fluid representing either ascites or blood. Three days after 
admission, the patient had no left foot pain but persistent back and abdominal pain. His hemoglobin was stable 
after transfusion and a repeat CT scan showed resolution of the psoas hematoma. Subsequently, vancomycin- 
resistant enterococcus faecium (VRE) peritonitis was diagnosed. Despite aggressive antibiotic therapy and sup-
portive care, the patient’s condition deteriorated progressively and he died a few days later. 
3. Discussion 
LSB is typically performed to improve lower extremity circulation and relieve pain in patients with peripheral 
vascular disease and complex regional pain syndrome. The lumbar ganglia aggregate at the anterolateral aspect 
of upper lumbar vertebral bodies are separated from the somatic nerves by the psoas muscle and the fascia.  
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Table 1. Admission lab data.                                                     
Variable Reference Range Adult, Male Patient’s value 
Hemoglobin (g/dl) 14 - 17 6.5 
Hematocrit (%) 41 - 51 19.7 
White blood cell count (per mm3) 4 × 103 - 10 × 103 17.1 × 103 
Platelet (per mm3) 150,000 - 350,000 133,000 
Prothrombin time (seconds) 11 - 13 13.8 
International normalized ratio   1.2 
Activated partial thromboplastin time (seconds) 30 - 40 26 
Blood urea nitrogen (mg/dl) 8 - 20 65 
Creatinine (mg/dl) 0.7 - 1.3 4.2 
Alanine aminotransferase (U/L) 0 - 35 173 
Aspartate aminotransferase (U/L) 0 - 35 85 
Albumin (g/dL) 3.5 - 5.5 2.7 
Creatine kinase MB (IU/L) 5 - 25  21.6 
Troponin I (ng/mL) 0 - 0.5 0.6 
 
 
Figure 1. Enlarged left psoas after the lumbar sympathetic block.             
 
The lumbar ganglia are in close proximity to the major vessels [4]. During a LSB, a block needle pierces the 
psoas fascia and well-perfused muscle [5]. The risk of bleeding from vascular injury is perceivable. Nevertheless, 
reports of hemorrhagic complication specifically from LSB are scarce. An English language literature search of 
Pubmed yielded one report of retroperitoneal hemorrhage after LSB in two patients, aged 71 and 79, with severe 
peripheral arterial disease and critical limb ischemia. The patients had been treated with ticlodipine or clopido-
grel [6]. 
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Anticoagulation by heparin, Coumadin, and thrombolytic agents is considered contraindication to regional 
anesthesia and nerve blocks. However, antiplatelet agents such as Aggrenox are considered low risk [7]. Each 
capsule of Aggrenox contains immediate-release aspirin 25 mg and extended-release dipyridamole 200 mg [1]. 
Aspirin decreases the amount of thromboxane A2, a powerful inducer of platelet aggregation and vasoconstric-
tor, by irreversibly inhibiting platelet cyclooxygenase. The inhibition of platelet cyclooxygenase can only be re-
versed by the production of new platelets. Approximately, 30% of platelet cyclooxygenase activity is recovered 
four days after cessation of aspirin [8]. Dipyridamole increases platelet cyclic-3',5'-adenosine monophosphate 
(cAMP) levels, resulting in lesser platelet aggregation in response to various stimuli such as platelet activating 
factor (PAF), collagen, and adenosine diphosphate (ADP). The half-life of extended-release dipyridamole is 
13.6 hours [9]. Both drugs are antithrombotic and have a synergistic effect with combined administration [10]. 
The drug label offers no advice on continuing or stopping Aggrenox around the time of a nerve block [1]. In our 
case, the medication was ceased three days prior to LSB, and this allowed for partial recovery of platelet func-
tion. More often than not, clinicians face the dilemma of continuing or stopping antiplatelet agents around the 
time of an interventional pain-relieving procedure because the consequences of both hemorrhagic and throm-
botic complications are devastating. 
Our case also exemplifies the difficultly caring for patients with complex medical co-morbidities in the 
chronic pain clinic. In addition to the residual effect of Aggrenox, our patient’s renal failure and abnormal liver 
function were likely contributing factors to his psoas hematoma. The formation of platelet plug is impaired in 
uremic patients due to a combination of factors that are either intrinsic or extrinsic to platelets [11]. Factors that 
are intrinsic to platelets are abnormal expression of platelet surface glycoproteins, decreased secretion of platelet 
granular contents (thromboxane A2, adenosine diphosphate, epinephrine and serotonin), and abnormal platelet 
cytoskeletal assembly. Factors that are extrinsic to platelets include defective interaction between platelet and 
vessel wall and between platelet and fibrinogen and anemia. Although our patient did not have frankly de-com- 
pensated liver cirrhosis, his low albumin level, marginal prothrombin time, and mildly depressed platelet count 
demonstrated hepatic dysfunction that likely further negatively impacted his hemostasis. It is also important to 
note that the patient survived form psoas hemorrhage but died from further complications of VRE peritonitis 
while in the hospital. 
The ASRA guideline published in 2010 entitled “Regional Anesthesia in the Patient Receiving Antithrombot-
ic or Therombolytic Therapy” made no specific recommendation regarding Aggrenox. However, the guideline 
stresses individualized decisions based on risk and benefit for each patient [3]. Raj et al. [12] proposed a tool 
which scores the patient-specific and technique-specific bleeding risk factors. The patient-specific factors in-
clude history of bleeding, results of coagulation studies, intake of medications known to affect hemostasis, and 
past medical history relevant to the integrity of the coagulation system. The technique-specific factors examine 
whether the target is in proximity to significant vascular/neurological structures and/or in a confined space. It 
also considers needle type (sharp versus blunt) and gauge, number of needle passages, the use of fluoroscopy, 
the presence of blood during aspiration, and the type of a procedure (single-shot versus continuous infusion). 
This allows physicians to quickly identify potential bleeding problems.  
4. Conclusion 
In conclusion, LSB is a commonly used technique in pain management for patients with severe peripheral ar-
terial disease who are not candidates for surgery or angioplasty. This patient population usually has multiple 
medical co-morbidities and has high risk for procedural complications. The occurrence of significant bleeding is 
rare based on published literature, despite the fact that the incidence of vascular puncture is certainly more 
common than reported. The pain practitioner must weigh the risks and benefits carefully and keep in mind the 
risks associated with the use of antiplatelet agents as well as those from discontinuation of such agents. Nerve 
blocks provide short term pain relief in general and long term pain control is achieved by repeated procedures. 
Complications from multiple procedures are conceivably higher than that from one time intervention. Clear 
communication must be maintained between the interventional pain physician and the patient.  
References 
[1] Furie, K.L., Kasner, S.E., Adams, R.J., Alberts, G.W., Bush, R.L., Fagan, S.C., Halperin, J.L., Johnston, S.C., Katzan, 
I., Kernan, W.N., Mitchell, P.H., Ovbiagele, B., Palesch, Y.Y., Sacco, R.L., Schwamm, L.H., Wassertheil-Smoller, S., 
N. Rizk et al. 
 
 103 
Turan, T.N. and Wentworth, D. (2011) Executive Summary: Guidelines for the Prevention of Stroke in Patients with 
Stroke or Transient Ischemic Attack. Stroke, 42, 227-276. http://dx.doi.org/10.1161/STR.0b013e3181f7d043  
[2] Feigin, V.L., Lawes, C.M.M., Bennett, D.A. and Anderson, C.S. (2003) Stroke Epidemiology: A Review of Popula-
tion-Based Studies of Incidence, Prevalence, and Case-Fatality in the Late 20th Century. The Lancet Neurology, 2, 
43-53. http://dx.doi.org/10.1016/S1474-4422(03)00266-7 
[3] Horlocker, T.T., Wedel, D.J., Rowlingson, J.C., Enneking, F.K., Kopp, S.L., Benzon, H.T., Brown, D.L., Heit, J.A., 
Mulroy, M.F., Rosenquist, R.W., Tryba, M. and Yuan, C. (2010) Regional Anesthesia in the Patient Receiving Antith-
rombotic or Thrombolytic Therapy, American Society of Regional Anesthesia and Pain Medicine Evidence-Based 
Guideline (3rd Edition). Regional Anesthesia and Pain Medicine, 35, 64-101. 
[4] Kauppila, L.I. (1994) Blood Supply of the Lower Thoracic and Lumbosacral Regions, Postmortem Aortography in 38 
Young Adults. Acta Radiologica, 35, 541-544. 
[5] Pillet, J., Chevalier, J.M., Rasomanana, D., Enon, B., Mercier, P., Lescalie, F., Moreau, F. and Cronier, P. (1989) The 
Principle Artery of the Psoas Major Muscle. Surgical-Radiologic Anatomy, 11, 33-36. 
http://dx.doi.org/10.1007/BF02102243 
[6] Maier, C., Gleim, M., Weiss, T., Stachetzki, U., Nicolas, V. and Zenz, M. (2002) Severe Bleeding Following Lumbar 
Sympathetic Blockade in Two Patients under Medication with Irreversible Platelet Aggregation Inhibitors. Anesthesi-
ology, 97, 740-743. http://dx.doi.org/10.1097/00000542-200209000-00032 
[7] Manchikanti, L., Falco, F.J.E., Benyamin, R.M., Caraway, D.L., Kaye, A.D., Helm II, S., Wargo, B.W., Hansen, H., 
Parr, A.T., Singh, V., Swicegood, J.R., Smith, H.S., Schultz, D.M., Malla, Y. and Hirsch, J.A. (2013) Assessment of 
Bleeding Risk of Interventional Techniques: A Best Evidence Synthesis of Practice Patterns and Perioperative Man-
agement of Anticoagulant and Antithrombotic Therapy. Pain Physician, 16, SE261-SE318. 
[8] Burch, J.W., Stanford, N. and Majerus, P.W. (1978) Inhibition of Platelet Prostaglandin Synthetase by Oral Aspirin. 
The Journal of Clinical Investigation, 61, 314-319. http://dx.doi.org/10.1172/JCI108941 
[9] Lenz, T.L. and Wilson, A.F. (2003) Clinical Pharmacokinetics of Antiplatelet Agents Used in the Secondary Preven-
tion of Stroke. Clinical Pharmacokinetics, 42, 909-920. http://dx.doi.org/10.2165/00003088-200342100-00003 
[10] Hervey, P.S. and Goa, K.L. (1999) Extended-Release Dipyridamole/Aspirin. Drugs, 58, 469-476. 
http://dx.doi.org/10.2165/00003495-199958030-00007 
[11] Kaw, D. and Malhotra, D. (2006) Platelet Dysfunction and End-Stage Renal Disease. Seminars in Dialysis, 19, 317- 
322. http://dx.doi.org/10.1111/j.1525-139X.2006.00179.x 
[12] Raj, P.P., Shah, R.V., Kaye, A.D., Denaro, S. and Hoover, J.M. (2004) Bleeding Risk in Interventional Pain Practice: 
Assessment, Management, and Review of the Literature. Pain Physician, 7, 3-51. 
